ATAI

#2139
AtaiBeckley Inc. Common Stock
4.3300 USD
-0.23%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
4.3300
4.3300
Годовой диапазон
3.2700
5.5000
Дневное изменение
-0.23%
Месячное изменение
+28.49%
6-месячное изменение
+9.62%
Годовое изменение
+9.62%
Предыдущее закрытие
4.3400
Открыть
4.3300
Минимум
4.3300
High
4.3300
Объем
64
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 1.5794 B
  • Employee 99
  • Founded 2018
  • CEO Florian Brand
  • Website www.ataibeckley.com
  • Headquarter Delaware, United States
  • FIGI BBG0107FR3K9
  • Industry Биотехнологии
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-1.41
Коэффициент цена/денежный поток
226.59

AtaiBeckley Inc

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.

Новости